Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and epidermal growth factor

erlotinib hydrochloride has been researched along with epidermal growth factor in 83 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(epidermal growth factor)		Trials
(epidermal growth factor)		Recent Studies (post-2010) (epidermal growth factor)
4,3537863,03324,1552174,699

Research

Studies (83)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's34 (40.96)29.6817
2010's41 (49.40)24.3611
2020's8 (9.64)2.80

Authors

AuthorsStudies
Sánchez De Cos Escuín, J1
Couzin, J1
Bonomi, P1
Belani, CP; Ramalingam, S1
Baker, M1
Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ1
Faj, D; Kurbel, S1
Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB1
Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P1
Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N1
Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S1
Herbst, R; Sandler, A1
Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P1
Birle, DC; Hedley, DW1
Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O1
Zalcman, G1
Burtness, B1
Argiris, A; Grandis, JR; Karamouzis, MV1
Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG1
Arnoletti, JP; Buchsbaum, DJ; Frolov, A; Frolova, N; Heslin, MJ; Howard, JH; Jhala, NC; Tzeng, CW; Vickers, SM1
Arango, D; Augenlicht, LH; Byun, DS; Goel, S; Jhawer, M; Klampfer, L; Ling, YH; Mariadason, JM; Montagna, C; Nasser, S; Perez-Soler, R; Shin, J; Soler, RP; Wilson, AJ1
Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C1
Gettinger, S1
Christodoulou, C; Dahabreh, J; Mavri, A; Murray, S; Nikolakopoulou, A; Petraki, K; Skarlos, D1
Holtkamp, N; Malzer, E; Mautner, VF; Mawrin, C; Mucha, J; Okuducu, AF; Schildhaus, HU; von Deimling, A; Zietsch, J1
Agulnik, M; Brockstein, B; Lacouture, M1
Dolman, ME; Fretz, MM; Goldschmeding, R; Hennink, WE; Kok, RJ; Lacombe, M; Nguyen, TQ; Pato, J; Prakash, J; Storm, G1
Owonikoko, TK; Ramalingam, S1
Andrew, AS; Duell, EJ; Mason, RA; Memoli, V1
Alkemade, JA; Bovenschen, HJ1
Hasmann, M; Klein-Scory, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schoeneck, A; Schulmann, K; Schwarte-Waldhoff, I; Stricker, I; Tannapfel, A1
España, A; López-Picazo, JM; López-Zabalza, MJ; Marquina, M; Pelacho, B; Pretel, M1
Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY1
de Stanchina, E; Goel, A; Gong, Y; Koutcher, JA; Mellinghoff, IK; Ouerfelli, O; Pao, W; Politi, KA; Regales, L; Shen, R; Spassova, M; Vivanco, I; Zakowski, MF1
Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N1
Hao, GK; Lan, W; Lan, WJ; Sun, R; Wang, J; Wang, RM; Wang, TF; Zhang, RH1
Ahsan, A; Bhojani, MS; Hegde, A; Helman, A; Hiniker, SM; Lawrence, TS; Menawat, R; Nyati, MK; Nyati, S; Ramanand, SG1
Dahm-Daphi, J; Dikomey, E; Holst, K; Kasten-Pisula, U; Kriegs, M; Rieckmann, T; Saker, J1
Abd Elmageed, ZY; Amin, AH; Matrougui, K; Partyka, M1
Burga, LN; Hofstatter, EW; Hu, H; Juvekar, A; Troyan, SL; Tung, NM; Wulf, GM1
Masago, K; Mishima, M; Miura, M; Togashi, Y; Toyama, Y1
Dao-Pick, T; DeFazio-Eli, L; Goodman, L; Parry, G; Strommen, K; Winslow, J1
Gunn, JR; Korc, M; Sempere, LF1
Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y1
Bade, LK; Dehut, HA; Goldberg, JE; Hall, MK; Schwertfeger, KL1
Glimelius, B; Häggblad Sahlberg, S; Lennartsson, J; Nygren, P; Spiegelberg, D; Stenerlöw, B1
Dhanesh, SB; James, J; Mundayoor, S; Shobana, S; Sivakumar, KC1
Chen, CH; Hsu, WM; Hu, RH; Huang, HC; Huang, J; Huang, MC; Huang, MJ; Lai, HS; Lee, JJ; Lee, PH; Liu, CH; Wu, YM1
Chen, C; Fujioka, N; Gupta, K; Gupta, V; Johnson, KN; Kratzke, RA; Li, Y; Nguyen, J; Niehans, G; Pasrija, T1
Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT1
Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T1
Al Saleh, S; Khajah, MA; Luqmani, YA; Mathew, PM1
El-Sawy, T; Esmaeli, B; Glisson, BS; Kies, MS; Lippman, S; Myers, JN; Sabichi, AL; William, WN1
Lyseng-Williamson, KA1
Chao, NJ; Chute, JP; Deoliviera, D; Doan, PL; Fixsen, E; Harris, JR; Helms, K; Himburg, HA; Kirsch, DG; Quarmyne, M; Russell, JL; Sullivan, JM1
Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L1
Deitz, S; Gore, J; Korc, M; Ouyang, H1
Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z1
Docheva, D; Eibl-Lindner, KH; Kampik, A; Kernt, M; Liegl, R; Wertheimer, C1
Koh, Y; Murakami, H; Serizawa, M; Takahashi, T; Watanabe, M; Yamamoto, N1
De, S; Dermawan, JK; Stark, GR1
Koskinen, PK; Palin, N; Rintala, JM; Rintala, SE; Savikko, J; von Willebrand, E1
Aldape, K; Berens, ME; Carrera-Silva, EA; Dietrich, JD; Errasti, AE; Ghosh, S; Gibbs, D; Hulme, C; Kusne, Y; Loftus, JC; Lu, Z; Mandell, EK; Perry, AS; Rothlin, CV; Rushing, EJ; Sanai, N; Yang, W1
Alexander, PB; Chen, J; Chen, R; Radiloff, DR; Sun, T; Wang, XF; Wu, H; Xiang, H; Yang, P; Yuan, L1
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG1
Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kim, CK; Kim, HG; Kim, HJ; Kim, SH; Lee, J; Lee, S; Oh, SY; Park, K; Park, MJ; Park, YS; Son, C; Song, KH; Sun, JM; Yi, SY1
Croniger, CM; De, S; DeSantis, D; Li, X; Stark, GR; Zhou, H1
Alves, F; Cardone, RA; Greco, MR; Nøhr-Nielsen, A; Pedersen, SF; Reshkin, SJ; Saccomano, M; Zeeberg, K1
Kannan, N; Katiyar, S; Ruan, Z1
Bao, J; Li, C; Shao, Y; Tan, G; Wu, AH; Yang, QC; Ye, L; Ye, LH; Zhou, Q1
Gao, MY; Lin, C; Qin, Y; Wang, YF; Zhang, H1
Dulger, N; Majeska, R; Pena, J; Redenti, S; Singh, T; Vazquez, M; Zhou, J1
Chhabra, R1
Astashchanka, A; Jacobsen, BM; Shroka, TM1
Golabiewska, E; Holownia, A; Niechoda, A; Rybak, A; Zarzecki, M1
Catapano, J; Czyż, J; Król, K; Pudełek, M; Ryszawy, D; Wróbel, T1
Gao, D; Liu, Y; Lu, L; Lu, SL; Mathes, D; Pomfret, EA; Qi, Z; Qiu, Y; Wang, Z; Zhang, H1
Bajan, S; Boonyaratanakornkit, V; Hutvagner, G; Kaewjanthong, P; McGowan, E; Sasano, H; Sooksai, S1
Acconcia, F1
Boutin, A; Eliseeva, E; Gershengorn, MC; Marcus-Samuels, B; Neumann, S1
Bhat, TA; Dheeraj, A; Nambiar, DK; Singh, RP; Singh, SP; Yim, DS1
Buzdin, A; Gaifullin, N; Garazha, A; Kamashev, D; Lebedev, T; Poddubskaya, E; Prassolov, V; Raevskiy, M; Sekacheva, M; Shaban, N; Sorokin, M; Suntsova, M1
Choi, SH; Hwang, SH; Kim, JH; Lee, R; Nah, SY; Won, KJ1

Reviews

11 review(s) available for erlotinib hydrochloride and epidermal growth factor

ArticleYear
[New therapeutic targets and strategies in lung cancer].
    Archivos de bronconeumologia, 2002, Volume: 38, Issue:8

    Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Erlotinib: a new therapeutic approach for non-small cell lung cancer.
    Expert opinion on investigational drugs, 2003, Volume: 12, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Tumor Cells, Cultured

2003
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-15, Volume: 12, Issue:14 Pt 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Synergism; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Vascular Endothelial Growth Factor A

2006
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines

2006
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha

2006
Her signaling in pancreatic cancer.
    Expert opinion on biological therapy, 2007, Volume: 7, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome

2007
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    JAMA, 2007, Jul-04, Volume: 298, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines

2007
Targeted therapy in rectal cancer.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A

2007
Targeted therapy in advanced non-small-cell lung cancer.
    Seminars in respiratory and critical care medicine, 2008, Volume: 29, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2008
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines

2008
Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.
    Molecular diagnosis & therapy, 2013, Volume: 17, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mutation; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; White People

2013

Trials

1 trial(s) available for erlotinib hydrochloride and epidermal growth factor

ArticleYear
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Disease Progression; Disease-Free Survival; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Ointments; Pancreatic Neoplasms; Protein Kinase Inhibitors; Republic of Korea; Treatment Outcome

2016

Other Studies

71 other study(ies) available for erlotinib hydrochloride and epidermal growth factor

ArticleYear
Cancer drugs. Smart weapons prove tough to design.
    Science (New York, N.Y.), 2002, Oct-18, Volume: 298, Issue:5593

    Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration

2002
Lung cancer: looking ahead in 2004.
    Clinical lung cancer, 2004, Volume: 5, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2004
EGFR inhibitors square off at ASCO.
    Nature biotechnology, 2004, Volume: 22, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Industry; Economic Competition; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines

2004
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
    Cancer biology & therapy, 2004, Volume: 3, Issue:12

    Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured

2004
Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands?
    Medical hypotheses, 2005, Volume: 64, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autocrine Communication; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Ligands; Models, Biological; Neoplasm Proteins; Neoplasms; Paracrine Communication; Quinazolines; Skin; Transforming Growth Factor alpha; Treatment Outcome

2005
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
    Cancer research, 2006, Feb-15, Volume: 66, Issue:4

    Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation

2006
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
    Cancer research, 2006, Feb-15, Volume: 66, Issue:4

    Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays

2006
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
    Cancer research, 2006, Mar-15, Volume: 66, Issue:6

    Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A

2006
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Cancer cell, 2006, Volume: 10, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays

2006
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Epidermal Growth Factor; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Ribosomal Protein S6; Signal Transduction; Sirolimus; Transplantation, Heterologous; Uterine Cervical Neoplasms

2006
[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
    Revue de pneumologie clinique, 2007, Volume: 63, Issue:1 Pt 2

    Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-2; Genes, ras; Humans; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Respiratory Mucosa

2007
EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
    The Journal of surgical research, 2007, Volume: 143, Issue:1

    Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction

2007
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
    Cancer research, 2008, Mar-15, Volume: 68, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Gene Dosage; Genes, ras; HCT116 Cells; Humans; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Quinazolines; ras Proteins; Resting Phase, Cell Cycle; RNA, Messenger

2008
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
    The Prostate, 2008, Jun-15, Volume: 68, Issue:9

    Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines

2008
Response of malignant thymoma to erlotinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Thymoma

2008
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Neuro-oncology, 2008, Volume: 10, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Genes, p16; Genes, p53; Humans; Immunohistochemistry; Nerve Sheath Neoplasms; Polymorphism, Single-Stranded Conformational; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Trastuzumab

2008
Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors.
    Journal of controlled release : official journal of the Controlled Release Society, 2008, Dec-18, Volume: 132, Issue:3

    Topics: Cells, Cultured; Chemistry, Pharmaceutical; Drug Carriers; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; Kidney Tubules, Proximal; Kinetics; Muramidase; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Quinazolines; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta

2008
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
    Current treatment options in oncology, 2008, Volume: 9, Issue:4-6

    Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A

2008
Arsenic activates EGFR pathway signaling in the lung.
    Toxicological sciences : an official journal of the Society of Toxicology, 2009, Volume: 109, Issue:2

    Topics: Adult; Aged; Amphiregulin; Analysis of Variance; Arsenic; Arsenites; Biomarkers; Bronchi; Cells, Cultured; Cyclin D1; Cycloheximide; EGF Family of Proteins; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; Middle Aged; Nails; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Compounds

2009
Erlotinib-induced dermatologic side-effects.
    International journal of dermatology, 2009, Volume: 48, Issue:3

    Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Chickenpox; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Herpesvirus 3, Human; Humans; Protein Kinase Inhibitors; Quinazolines; Virus Activation

2009
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dimerization; Drug Therapy, Combination; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays

2009
An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris.
    Experimental dermatology, 2009, Volume: 18, Issue:9

    Topics: Acantholysis; Animals; Apoptosis; Betacellulin; Carrier Proteins; Disease Models, Animal; Enzyme Activation; Epidermal Growth Factor; Epidermis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoglobulin G; Intercellular Signaling Peptides and Proteins; Intradermal Tests; Isoenzymes; Mice; Mice, Inbred C57BL; Pemphigus; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Sirolimus; src-Family Kinases; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha

2009
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
    Journal of receptor and signal transduction research, 2009, Volume: 29, Issue:3-4

    Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2009
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
    The Journal of clinical investigation, 2009, Volume: 119, Issue:10

    Topics: Afatinib; Amphiregulin; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Models, Animal; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Transplantation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured

2009
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
    American journal of respiratory and critical care medicine, 2010, Jan-15, Volume: 181, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance

2010
Duplexed on-microbead binding assay for competitive inhibitor of epidermal growth factor receptor by quantitative flow cytometry.
    Basic & clinical pharmacology & toxicology, 2010, Volume: 107, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Competitive Bidding; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Microspheres; Protein Binding; Protein Kinase Inhibitors; Quinazolines

2010
Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.
    Cancer research, 2010, Apr-01, Volume: 70, Issue:7

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phosphorylation; Proto-Oncogene Proteins c-cbl; Quinazolines; Ubiquitin

2010
The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
    DNA repair, 2010, Aug-05, Volume: 9, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bronchi; Cell Line, Tumor; Cetuximab; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Quinazolines; RNA, Small Interfering; Signal Transduction

2010
Mechanisms of myogenic tone of coronary arteriole: Role of down stream signaling of the EGFR tyrosine kinase.
    Microvascular research, 2011, Volume: 81, Issue:1

    Topics: Animals; Arterioles; Cells, Cultured; Coronary Vessels; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; GRB2 Adaptor Protein; Janus Kinases; Mice; Mice, Inbred C57BL; Models, Biological; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosin Light Chains; Nitroprusside; Phosphorylation; Potassium Chloride; Pressure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Son of Sevenless Proteins; STAT Transcription Factors; STAT3 Transcription Factor; Tyrphostins; Vasoconstriction; Vasodilation

2011
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
    Breast cancer research : BCR, 2011, Mar-11, Volume: 13, Issue:2

    Topics: Aldehyde Dehydrogenase 1 Family; Animals; BRCA1 Protein; Breast; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, BRCA1; Genes, p53; Humans; Isoenzymes; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Retinal Dehydrogenase; RNA Interference

2011
Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16

    Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma, Signet Ring Cell; DNA Mutational Analysis; Epidermal Growth Factor; Erlotinib Hydrochloride; Exons; Female; Humans; Immunohistochemistry; Mutation; Polymerase Chain Reaction; Quinazolines; Thyroid Neoplasms

2011
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
    Breast cancer research : BCR, 2011, Apr-15, Volume: 13, Issue:2

    Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Staining and Labeling; Treatment Outcome

2011
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media; Deoxycytidine; Dioxoles; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gemcitabine; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment

2011
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines

2012
Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
    Journal of cell science, 2011, Sep-15, Volume: 124, Issue:Pt 18

    Topics: Amphiregulin; Animals; Breast Neoplasms; Cell Growth Processes; Cell Line; Cell Movement; Cell Transformation, Neoplastic; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Mammary Glands, Human; MAP Kinase Signaling System; Mice; Mice, Transgenic; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1

2011
The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines.
    International journal of oncology, 2012, Volume: 40, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colonic Neoplasms; Drug Delivery Systems; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; HCT116 Cells; HT29 Cells; Humans; Quinazolines; Radiation-Sensitizing Agents; Recombinant Fusion Proteins; Signal Transduction

2012
A systems biology approach to model neural stem cell regulation by notch, shh, wnt, and EGF signaling pathways.
    Omics : a journal of integrative biology, 2011, Volume: 15, Issue:10

    Topics: Basic Helix-Loop-Helix Transcription Factors; Computer Simulation; Epidermal Growth Factor; Erlotinib Hydrochloride; Gene Expression; Gene Expression Regulation; Hedgehog Proteins; Homeodomain Proteins; Humans; Models, Biological; Neural Stem Cells; Protein Interaction Mapping; Protein Kinase Inhibitors; Quinazolines; Receptors, Notch; Signal Transduction; Systems Biology; Transcription Factor HES-1; Wnt Proteins

2011
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
    Cancer research, 2011, Dec-01, Volume: 71, Issue:23

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glycosylation; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mucins; N-Acetylgalactosaminyltransferases; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polypeptide N-acetylgalactosaminyltransferase; Quinazolines; RNA, Messenger

2011
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
    Anesthesia and analgesia, 2011, Volume: 113, Issue:6

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morphine; Quinazolines; Receptors, Opioid, mu

2011
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.
    Clinical & experimental metastasis, 2012, Volume: 29, Issue:3

    Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand

2012
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    International journal of oncology, 2012, Volume: 41, Issue:3

    Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger

2012
Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Benzamides; Breast Neoplasms; Cell Movement; Cell Proliferation; Chemokine CCL5; Chromones; Collagenases; Diphenylamine; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor I; Lymphokines; MCF-7 Cells; Morpholines; Phosphorylation; Platelet-Derived Growth Factor; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Estrogen; RNA, Small Interfering; Transforming Growth Factor beta

2012
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2012, Volume: 130, Issue:12

    Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Male; Orbital Neoplasms; Protein Kinase Inhibitors; Quinazolines

2012
Epidermal growth factor regulates hematopoietic regeneration after radiation injury.
    Nature medicine, 2013, Volume: 19, Issue:3

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Hematopoiesis; Hematopoietic Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries, Experimental; Regeneration; Signal Transduction; Tumor Suppressor Proteins; Whole-Body Irradiation

2013
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
    The Prostate, 2013, Volume: 73, Issue:13

    Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1

2013
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.
    Oncogene, 2014, Sep-18, Volume: 33, Issue:38

    Topics: Acetyltransferases; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Transforming Growth Factor beta

2014
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Feb-01, Volume: 192, Issue:3

    Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells

2014
EGFR-blockade with erlotinib reduces EGF and TGF-β2 expression and the actin-cytoskeleton which influences different aspects of cellular migration in lens epithelial cells.
    Current eye research, 2014, Volume: 39, Issue:10

    Topics: Actin Cytoskeleton; Cell Movement; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lens, Crystalline; Microscopy, Fluorescence; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Time-Lapse Imaging; Transforming Growth Factor beta2

2014
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
    Cancer science, 2014, Volume: 105, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta2; Wound Healing

2014
EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Aug-12, Volume: 111, Issue:32

    Topics: Breast; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Humans; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOS1 Protein; Up-Regulation

2014
Epidermal growth factor inhibition, a novel pathway to prevent chronic allograft injury.
    Transplantation, 2014, Oct-27, Volume: 98, Issue:8

    Topics: Animals; Aorta; Chronic Disease; Epidermal Growth Factor; Erlotinib Hydrochloride; Graft Rejection; Immunohistochemistry; Kidney; Kidney Transplantation; Male; Quinazolines; Rats; Rats, Wistar; Transplantation, Homologous

2014
Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.
    Science signaling, 2014, Aug-12, Volume: 7, Issue:338

    Topics: Animals; Carcinogenesis; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Kaplan-Meier Estimate; Mice; NF-kappa B; Paracrine Communication; Protein Kinase C; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Necrosis Factor-alpha

2014
EGF promotes mammalian cell growth by suppressing cellular senescence.
    Cell research, 2015, Volume: 25, Issue:1

    Topics: Animals; Cell Line; Cell Proliferation; Cells, Cultured; Cellular Senescence; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines

2015
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib

2015
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Aug-04, Volume: 112, Issue:31

    Topics: Animals; Cell Line; Cytokines; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Humans; Lipopolysaccharides; MAP Kinase Kinase Kinases; Mice; Myeloid Differentiation Factor 88; NF-kappa B; Phosphorylation; Protective Agents; Proto-Oncogene Mas; Quinazolines; Signal Transduction; src-Family Kinases; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha

2015
Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:1

    Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Stromal Cells

2016
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
    Biochemistry, 2017, Jan-10, Volume: 56, Issue:1

    Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines

2017
A murine model of dry eye induced by topical administration of erlotinib eye drops.
    International journal of molecular medicine, 2018, Volume: 41, Issue:3

    Topics: Administration, Topical; Animals; Cell Count; Cornea; Disease Models, Animal; Dry Eye Syndromes; Epidermal Growth Factor; Epithelium; Erlotinib Hydrochloride; Goblet Cells; Inflammation; Male; Mice, Inbred BALB C; Ophthalmic Solutions; Phosphorylation; Tears; Tumor Necrosis Factor-alpha

2018
EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non‑small cell lung cancer cells.
    Oncology reports, 2018, Volume: 40, Issue:1

    Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Quinazolines; Telomerase; Tyrphostins

2018
Controlled microenvironments to evaluate chemotactic properties of cultured Müller glia.
    Experimental eye research, 2018, Volume: 173

    Topics: Animals; Cell Proliferation; Cells, Cultured; Cellular Microenvironment; Chemotaxis; Ependymoglial Cells; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Fibroblast Growth Factor 2; Fibroblast Growth Factor 8; Glial Fibrillary Acidic Protein; MAP Kinase Signaling System; Microfluidic Analytical Techniques; Nestin; Protein Kinase Inhibitors; Rats; Real-Time Polymerase Chain Reaction; Receptors, Growth Factor; RNA, Messenger; Vascular Endothelial Growth Factor A

2018
let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer.
    Scientific reports, 2018, 05-18, Volume: 8, Issue:1

    Topics: Cell Line, Tumor; Chromones; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; MicroRNAs; Morpholines; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Signal Transduction; SOXB1 Transcription Factors; Up-Regulation; Uterine Cervical Neoplasms

2018
Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.
    Breast cancer research and treatment, 2019, Volume: 173, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mucin-2; RNA, Small Interfering; Xenograft Model Antitumor Assays

2019
Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells.
    Advances in experimental medicine and biology, 2019, Volume: 1153

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cells; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neuraminidase; Protein Kinase Inhibitors; Quinazolines

2019
Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling.
    International journal of molecular sciences, 2020, May-20, Volume: 21, Issue:10

    Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitochondria; Reactive Oxygen Species; Signal Transduction

2020
A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
    Molecular oncology, 2021, Volume: 15, Issue:4

    Topics: Animals; Cell Line, Tumor; Diphtheria Toxin; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Recombinant Fusion Proteins; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

2021
Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
    PloS one, 2022, Volume: 17, Issue:3

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Peptides; Protein Kinase Inhibitors; Receptors, Progesterone

2022
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19

    Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen

2022
Opposing Effects of EGF Receptor Signaling on Proliferation and Differentiation Initiated by EGF or TSH/EGF Receptor Transactivation.
    Endocrinology, 2022, 10-23, Volume: 163, Issue:12

    Topics: Cell Proliferation; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Ligands; Panitumumab; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Thyrotropin; Thyrotropin; Transcriptional Activation

2022
Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
    The Prostate, 2023, Volume: 83, Issue:6

    Topics: Carcinoma; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Ligands; Male; MAP Kinase Signaling System; Phosphorylation; Prostate; Prostatic Neoplasms

2023
Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways.
    Cells, 2023, 08-08, Volume: 12, Issue:16

    Topics: Carcinoma, Squamous Cell; Cell Cycle; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Serum

2023
Gintonin-Induced Wound-Healing-Related Responses Involve Epidermal-Growth-Factor-like Effects in Keratinocytes.
    International journal of molecular sciences, 2023, Sep-14, Volume: 24, Issue:18

    Topics: Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Heparin-binding EGF-like Growth Factor; Keratinocytes

2023